Record of the Meeting of the Advsiory Committee on Immunization Practices
The meeting report outlines the committee's recommendations for introduction of RotaTeq® into the routine US immunization schedule and provides guidance on addressing special circumstances in relation to administration of the vaccine. The document also describes proposed activities by the US Food and Drug Administration and the CDC to monitor the safety of RotaTeq® vaccine following immunization and summarizes data from Phase 3 safety and efficacy studies of RotaTeq®.
Author(s): US Centers for Disease Control and Prevention
Download file (English)
1,336 KB PDF